Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics

• Published in: Translational neurodegeneration 2023-10, Vol.12 (1), p.48-48, Article 48
• Main Authors: Lepiarz-Raba, Izabela, Gbadamosi, Ismail, Florea, Roberta, Paolicelli, Rosa Chiara, Jawaid, Ali
• Format: Article
• Language: English
• Subjects: Adenosine triphosphate; Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Brain - metabolism; Cytokines; Energy; Flexibility; Glucose; Homeostasis; Humans; Inflammation; Lipids; Metabolism; Metabolites; Microglia; Microglia - metabolism; Neurodegeneration; Nutrients; Phagocytosis; Phosphorylation; Proteins; Review; Synapses; Tumor necrosis factor-TNF
• ISSN: 2047-9158; 2047-9158
• DOI: 10.1186/s40035-023-00382-w

Microglia, the resident immune cells of the brain, are increasingly implicated in the regulation of brain health and disease. Microglia perform multiple functions in the central nervous system, including surveillance, phagocytosis and release of a variety of soluble factors. Importantly, a majority of their functions are closely related to changes in their metabolism. This natural inter-dependency between core microglial properties and metabolism offers a unique opportunity to modulate microglial activities via nutritional or metabolic interventions. In this review, we examine the existing scientific literature to synthesize the hypothesis that microglial phagocytosis of amyloid beta (Aβ) aggregates in Alzheimer's disease (AD) can be selectively enhanced via metabolic interventions. We first review the basics of microglial metabolism and the effects of common metabolites, such as glucose, lipids, ketone bodies, glutamine, pyruvate and lactate, on microglial inflammatory and phagocytic properties. Next, we examine the evidence for dysregulation of microglial metabolism in AD. This is followed by a review of in vivo studies on metabolic manipulation of microglial functions to ascertain their therapeutic potential in AD. Finally, we discuss the effects of metabolic factors on microglial phagocytosis of healthy synapses, a pathological process that also contributes to the progression of AD. We conclude by enlisting the current challenges that need to be addressed before strategies to harness microglial phagocytosis to clear pathological protein deposits in AD and other neurodegenerative disorders can be widely adopted.